THE hemolytic anemia associated with erythrocyte pyruvate kinase deficiency is of variable severity 1–17 and probably of variable cause. In some cases severe aberrations of erythrocyte shape ...

Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.

SL1009 is expected to increase energy production by inhibiting pyruvate dehydrogenase kinase and stimulating residual pyruvate dehydrogenase complex activity. The NDA is supported by data from a ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...